Introduction
============

Primary lung cancer is the leading cause of cancer-related death worldwide[@B1]. The vast majority of cancer-related deaths are due to metastasis, or spreading of the disease beyond the primary tumor site. Metastasis occurs when cells are shed from the primary tumor and circulate in the blood. It is these circulating tumor cells (CTCs) that constitute the seeds for subsequent growth of metastatic tumors in distant organs, such as the liver, brain, or bone marrow.

Cancer biomarkers may reveal important clues about clinical course or outcome. CTCs are candidate biomarkers that may be able to assess disease progression before patients become symptomatic. The prognostic utility of CTCs in lung cancer has been investigated[@B2]-[@B9]. Early stage NSCLC patients who had detectable CTC were most likely to develop subsequent metastatic recurrence[@B10]. It is also possible that CTCs harbor molecular information that cannot be obtained from other serum tumor markers and that may be useful in guiding decisions involving the administration of targeted therapies.

However, there is controversy regarding the incidence and clinical significance of CTCs in NSCLC, particularly in Chinese patients. While some studies have reported that detection of CTCs was significantly associated with shorter survival[@B2]-[@B3], [@B6]-[@B8], other studies have failed to identify any association between the presence of CTCs and prognosis[@B9]. Recently, a meta-analysis, which included 20 studies comprised of 1576 patients, showed that the presence of CTCs indicated a poor prognosis in patients with NSCLC[@B11].

Recently, the US Food and Drug Administration approved the CELLSEARCH® System (Veridex, Raritan, NJ, USA) as a novel technology to detect CTCs[@B12]-[@B13]. The clinical value of CTCs in lung cancer patients has not been fully explored. The major objective of this study was to assess whether the presence of CTCs in lung cancer patients prior to therapy correlated with other clinical parameters.

Materials and methods
=====================

Patients
--------

Patients were treated at the First Hospital of Jilin University (Changchun, Jilin, China). The study was approved by the Ethics Committee of the First Hospital of Jilin Medical University, and conducted according to the World Medical Association Declaration of Helsinki on ethical principles for medical research involving human subjects. Patients signed a written informed consent prior to the initiation of the study.

Patients had histologically confirmed lung cancer and did not have a previous cancer history. They had not yet undergone any treatment, including surgery, radiotherapy, chemotherapy or any other anti-cancer therapy. Thoracic CT scan, abdominal CT scan, brain MRI and bone scanning were used for TNM staging (7^th^ edition, 2009[@B14]), with which SCLC patients were further stratifiedby stages I, II, and III for correlation analysis of SCLC stages with CTC.

CTC analysis
------------

Peripheral blood samples were collected for CTC analysis within 7 days prior to the initiation of treatment. Measurements prior to treatment were considered baseline. Blood samples were collected in 10 ml Cell Save Preservation tubes, stored at room temperature, and processed within 96 hr of collection, according to the manufacturer\'s instructions (Veridex). CTC analysis was performed using the CELLSEARCH® System (Veridex) as previously described[@B12]-[@B13]. Ferrofluid nanoparticles coated with a polymer layer carrying biotin analogues and conjugated with antibodies against epithelial cell adhesion molecule (EpCAM) were used to initially capture putative CTCs, which were then magnetically separated from the remaining blood components. The isolated cells were fluorescently stained with specific antibody conjugates, such as CD45 (a leukocyte marker) and cytokeratins 8, 18, and 19 (CKs), and imaged for record. To be considered a CTC, a cell must be CD45 negative, contain a nucleus, and exhibit positive staining for cytoplasmic CKs.

Serum tumor marker analysis
---------------------------

Determination of serum tumor markers was performed on the Luminex 200 System with xMAP® technology (Luminex; Austin, TX, USA), including carcinoembryonic antigen (CEA), cancer antigen (CA) 19-9, CA-125, squamous cell carcinoma antigen (SCC-Ag), cytokeratin-19 fragments antigen 21-1 (CYFRA21-1), and neuron-specific enolase (NSE). The upper limits of normal values are 5 ng/mL for CEA, 35 U/mL for CA19-9, 35 U/mL for CA-125, 1.5 ng/mL for SCC-Ag, 5 ng/mL for CYFRA21-1, and 20 ng/mL for NSE.

Statistical analysis
--------------------

Univariate Fisher test analysis and multivariate logistic regression were used to evaluate the relationships between clinicopathologic data and CTC count thresholds in lung cancer patients, as well as the association between tumor markers and CTC count thresholds. In the multivariate logistic regression analysis, all categorical variables were set as dummy variables. The first category of each variable was selected as the baseline. All analyses were performed with SPSS v19.0 software (SPSS, Inc.; Chicago, IL, USA). A *P*-value \< 0.05 was considered statistically significant.

Results
=======

CTCs are detected in both NSCLC and SCLC patients
-------------------------------------------------

Clinical parameters, CTC count, and tumor markers are shown in **Table [1](#T1){ref-type="table"}**. Patients were simultaneously tested for other serum markers typically used in the clinical evaluation of lung cancer. Levels of serum CEA, NSE, Cyfra21-1, CA19-9, CA-125, and SCC-Ag were detectable in 173, 171, 173, 126, 118, and 122 patients, respectively. The median follow-up for all patients was 1 yr but we cannot yet evaluate survival outcomes.

Among patients enrolled in the study, 169 patients had NSCLC (63.8%) and 96 patients had SCLC (36.2%). CTCs were detected in 32.8% patients, with 40 cases in patients with NSCLC and 47 cases in patients with SCLC. A typical image of a CTC is shown in **Figure [1](#F1){ref-type="fig"}**.

Univariate analysis of CTC count with clinico-pathological variables
--------------------------------------------------------------------

No significant differences were observed for the association between any threshold CTC count and gender, age (≤ 60 or \> 60 yr), or smoking status. However, an association was found with histology. Of the 87 patients who had detectable CTCs (CTC count of ≥ 1/7.5ml), 40 were histologically categorized as NSCLC (23.7%) and 47 as SCLC (49.0%) (**Table [2](#T2){ref-type="table"}**). The predominance of NSCLC patients was observed at all CTC thresholds (CTCs ≥ 1, 2or5 /7.5ml) (*P*\< 0.05).

The presence of CTCs was associated with advanced tumor stage (*P*\< 0.05 for CTC thresholds ≥1 and 2/7.5 ml blood); the percentage of lung cancer patients who had detectable CTC increased from 1/17 (5.9%) at stage I to 46/126 (36.5%) at stage IV (**Table [2](#T2){ref-type="table"}**).

Tumor size and invasiveness, and local lymphatic metastasis were all associated with CTC count at thresholds ≥ 1 or 5/7.5 ml (*P*\< 0.05), respectively (**Table [2](#T2){ref-type="table"}**). The number of patients with detectable CTCs increased from 14/40 (35.0%) at T1 to 27/58 (46.6%) at T4 (CTC threshold ≥ 1/7.5 ml blood). Lymphatic metastasis was found in 4/40 (10.0 %) patients at N0 and in 19/76 (25.0%) patients at N3 (CTCs ≥ 5/7.5 ml blood). However, no relationship between CTC count and distant metastasis was observed. In patients with NSCLC, distant metastasis was found in 11/75 (14.7%) M0 patients compared to 29/94 (30.9%) M1 patients who had CTCs (CTCs ≥ 1/7.5 ml blood, *P*\< 0.05, and CTCs ≥ 2and 5/7.5 ml blood, *P*\< 0.05). However, in patients with SCLC, no statistical difference was observed at any CTC threshold (CTCs ≥ 1, 2 or 5/7.5ml).

Multivariate analysis demonstrates that CTCs correlate with advanced stage and histology of SCLC
------------------------------------------------------------------------------------------------

To identify a patient profile that predicts the presence of detectable CTC, multivariate analysis was performed using age, gender, smoking history, histology, and clinical stage. Lung cancer patients with either stage IV disease or SCLC histology had a higher incidence of detectable CTCs (P \< 0.05, **Table [3](#T3){ref-type="table"}**).

Lung cancer CTCs correlate with serum NSE levels
------------------------------------------------

No significant correlation was found between lung cancer CTC count and serum tumor markers, CA-125, CA19-9, Cyfra21-1, and SCC-Ag (**Table [3](#T3){ref-type="table"}**), but there was an association of CTCs with serum NSE (**Table [4](#T4){ref-type="table"}**). After adjustment for TNM stage (I, II, III and IV) and histology (SCLC and NSCLC), serum NSE levels were still associated with the CTC count. Results were similar when CTC thresholds ≥ 2and 5/7.5 ml were used (**Table [5](#T5){ref-type="table"}**). A similar non-significant trend was also observed with CEA.

Discussion
==========

The measurement of CTCs offers potential utility as a prognostic, predictive, and/or pharmacodynamic biomarker[@B12], [@B15]-[@B19]. While multiple studies have examined the prevalence and prognostic utility of CTCs in lung cancer[@B2]-[@B9], [@B11], only a few have addressed whether CTCs are related to other clinical parameters. This information may be useful in order to identify subgroups of lung cancer patients in whom CTC status might be therapeutically useful. Our data show that CTCs were independently correlated with three clinical characteristics: advanced stage IV disease, SCLC histology, and elevated serum NSE.

Univariate analysis revealed that CTC count significantly increased in parallel with TNM stage (from I to IV), tumor size and invasiveness, lymphatic metastasis, and histology. CTCs have been shown to display sensitivity and specificity in distinguishing clinical stage as well as histology (SCLC versus NSCLC) in other studies[@B10].

The CTC has been recently recommended by the American Society of Clinical Oncology (ASCO) as a potentially acceptable tumor marker for breast cancer patients[@B20]. In our study, a rigorous analysis was performed to determine the relevance of CTC count to standard tumor markers used in the diagnosis and clinical management of lung cancer patients. Although CTCs were found to correlate with levels of CYFRA21-1 in a previous, smaller study[@B21], serum NSE was the only tumor marker found to be associated with CTCs in our study. Other investigators have reported that serum NSE levels were associated with prognosis[@B22].The biological basis for the correlation between lung cancer CTCs and NSE will be the focus of future studies.

Others have previously shown that CTCs are correlated with the presence of distant metastasis[@B23] in lung cancer[@B24]. However, no relationship between any CTC threshold and distant metastasis was seen in our study. However, when cases with distant metastasis were divided on the basis of histologic subtype (NSCLC or SCLC), the presence of CTC was found to be associated with distant metastasis only in NSCLC.

Using tumor progression models, it has been reported that tumor cells can spread to distant sites even at pathologically early stages in tumor development[@B25]-[@B26]. In support of this finding, tumor cells have been detected in the peripheral blood of patients with early stage malignant epithelial tumors[@B27]. In a prospective study of lung cancer patients[@B10], CTCs were detected in 17/88 (19.3%) clinical stage I patients where distant metastases (all intrapulmonary metastases) were confirmed in two of 17 cases. Similarly, we found that CTCs were detected in 1/17 (5.9%) and 3/19 (15.8%) stage I and stage II patients, respectively. Long-term follow-up of these patients may determine whether the CTC count can eventually be correlated with the development of micrometastasis which ultimately leads to postoperative recurrence.

Finally, our multivariate analysis revealed that the detection of CTCs was correlated with histologic type (NSCLC and SCLC) and TNM stage (I, II, III and IV), but no significant correlation was observed with age, gender, and smoking status. In summary, our data indicate that CTCs are most likely to be found in patients who present with any one of three clinical characteristics: SCLC histology, stage IV disease, or elevated serum levels of NSE. A longer follow-up of the present cohort of patients using CTC testing may lead to a better understanding of disease progression.
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![**Immunostaining of a single lung cancer CTC isolated from peripheral blood.** Positive immunomagnetic selection with anti-EpCAM Ab was followed by morphological confirmation with staining for cytokeratins (cytoplasm), DAPI (nucleus), and CD45 (negative).](jcav08p3099g001){#F1}

###### 

Clinical characteristics, CTC count, and tumor markers of lung cancer patients.

  Characteristics   Number (%)   
  ----------------- ------------ -------------
  Gender            Male         174 (65.7%)
                    Female       91 (34.3%)
  Age               \< 60        102 (38.5%)
                    ≥ 60         163 (61.5%)
  Histology         NSCLC        169 (63.8%)
                    SCLC         96 (36.2%)
  Smoking status    Never        105 (39.6%)
                    Former       47 (17.7%)
                    Current      113 (42.6%)
  Clinical Stage    I            17 (6.4%)
                    II           19 (7.2%)
                    III          97 (36.6%)
                    IV           126 (47.5%)
  CTC count         ≥ 1          87 (32.8%)
                    ≥ 2          58 (21.9%)
                    ≥ 5          41 (15.5%)
  CEA               Elevated     77 (43.8%)
                    Normal       96 (56.3%)
  NSE               Elevated     53 (31.0%)
                    Normal       118 (69.0%)
  Cyfra21-1         Elevated     62 (35.8%)
                    Normal       111 (64.2%)
  CA199             Elevated     16 (12.7%)
                    Normal       110 (87.3%)
  CA125             Elevated     45 (38.1%)
                    Normal       73 (61.9%)
  SCC-Ag            Elevated     7 (5.7%)
                    Normal       115 (94.3%)

###### 

Univariate analysis between CTC count (per 7.5 mL of peripheral blood) and clinical-pathological data.

  -----------------------------------------------------------------------------------------------------------------
  Characteristic   \< 1\     ≥ 1\      *P*value   \< 2\   ≥ 2\      *P*value   \< 5\   ≥ 5\      *P*Value   
                   (%)       (%)                  (%)     (%)                  (%)     (%)                  
  ---------------- --------- --------- ---------- ------- --------- ---------- ------- --------- ---------- -------
  Gender           Male      118       56                 137       37                 147       27         

                             (67.8 )   (32.2 )            (78.7)    (21.3)             (84.5)    (15.5)     

                   Female    60        31         0.784   70        21         0.756   77        14         1.000

                             (65.9)    (34.1)             (76.9)    (23.1)             (84.6)    (15.4)     

  Age              \<60      107       56                 123       40                 133       30         

                             (65.6)    (34.4)             (75.5)    (24.5)             (81.6)    (18.4)     

                   ≥60       71        31         0.591   84        18         0.223   91        11         0.116

                             (69.6)    (30.4)             (82.4)    (17.6)             (89.2)    (10.8)     

  Histology        NSCLC     129       40                 149       20                 156       13         

                             (76.3)    (23.7)             (88.2)    (11.8)             (92.3)    (7.7)      

                   SCLC      49        47         0.000   58        38         0.000   68        28         0.000

                             (51.0)    (49.0)             (60.4)    (39.6)             (70.8)    (29.2)     

  Smoking          Never     72        33                 85        20                 89        16         

  status                     (68.6)    (31.4)             (81.0)    (19.0)             (84.8)    (15.2)     

                   Former    29        18                 33        14                 38        9          

                             (61.7)    (38.3)             (70.2)    (29.8)             (80.9)    (19.1)     

                   Current   77        36         0.688   89        24         0.337   97        16         0.713

                             (68.1)    (31.9)             (78.8)    (21.2)             (85.8)    (14.2)     

  clinical         I         16        1                  16        1                  16        1          

                             (94.1)    (5.9)              (94.1)    (5.9)              (94.1)    (5.9)      

  TNM              II        16        3                  19        0                  19        0          

  stage                      (84.2)    (15.8)             (100.0)   (0.0)              (100.0)   (0.0)      

                   III       64        33                 74        23                 80        17         

                             (66.0)    (34.0)             (76.3)    (30.3)             (82.5)    (17.5)     

                   IV        80        46         0.023   94        32         0.016   105       21         0.153

                             (63.5)    (36.5)             (74.6)    (25.4)             (83.3)    (16.7)     

  T                T1        26        14                 32        8                  37        3          

                             (65.0)    (35.0)             (80.0)    (20.0)             (92.5)    (7.5)      

                   T2        67        16                 72        11                 74        9          

                             (80.7)    (19.3)             (86.7)    (13.3)             (89.2)    (10.8)     

                   T3        39        22                 47        14                 51        10         

                             (63.9)    (36.1)             (77.0)    (23.0)             (83.6)    (16.4)     

                   T4        31        27         0.006   39        19         0.050   44        14         0.091

                             (53.4)    (46.6)             (67.2)    (32.8)             (75.9)    (24.1)     

  N                N0        32        8                  35        5                  36        4          

                             (80.0)    (20.0)             (87.5)    (12.5)             (90.0)    (10.0)     

                   N1        19        6                  23        2                  24        1          

                             (76.0)    (24.0)             (92.0)    (8.0)              (96.0)    (4.0)      

                   N2        75        44                 90        29                 102       17         

                             (63.0)    (37.0)             (75.6)    (24.4)             (85.7)    (14.3)     

                   N3        48        28         0.150   54        22         0.058   57        19         0.043

                             (63.2)    (36.8)             (71.1)    (28.9)             (75.0)    (25.0)     

  M                M0        98        41                 113       26                 119       20         

                             (70.5)    (29.5)             (81.3)    (18.7)             (85.6)    (14.4)     

                   M1        80        46         0.241   94        32         0.234   105       21         0.615

                             (63.5)    (36.5)             (74.6)    (25.4)             (83.3)    (16.7)     

  NSCLC            M0        64        11                 73        2                  73        2          

                             (85.3)    (14.7)             (97.3)    (2.7)              (97.3)    (2.7)      

                   M1        65        29         0.018   76        18         0.001   83        11         0.040

                             (69.1)    (30.9)             (80.9)    (19.1)             (88.3)    (11.7)     

  SCLC             M0        34        30                 40        24                 46        18         

                             (53.1)    (46.9)             (62.5)    (37.5)             (71.9)    (28.1)     

                   M1        15        17         0.666   18        14         0.659   22        10         0.814

                             (46.9)    (53.1)             (56.3)    (43.8)             (68.8)    (31.3)     
  -----------------------------------------------------------------------------------------------------------------

###### 

Multivariate analysis of the CTC positive model with adjusted odds ratios and 95% CI

  Risk factors      Exp (B)   95% CI         P-value
  ----------------- --------- -------------- ---------
  Gender                                     
  Female            1.00      Reference      \-
  Male              1.250     0.654-2.387    0.499
  Age                                        
  ≥ 60              1.00      Reference      \-
  \<60              0.784     0.434-1.418    0.421
  Smoking history                            0.465
  Never             1.00      Reference      \-
  Ever              1.627     0.714-3.705    0.246
  Current           1.063     0.532-2.124    0.862
  Clinical stage                             0.058
  I                 1.00      Reference      \-
  II                3.270     0.295-36.227   0.334
  III               6.001     0.742-48.566   0.093
  IV                9.377     1.182-74.386   0.034
  Histology                                  
  NSCLC             1.00      Reference      \-
  SCLC              3.002     1.656-5.444    0.000

###### 

Associations between CTC count and tumor markers.

  ---------------------------------------------------------------------------------------------------------------
  Characteristic   \< 1\      ≥ 1\     *P*value   \< 2\   ≥ 2\     *P*value   \< 5\   ≥ 5\     *P*value   
                   (%)        (%)                 (%)     (%)                 (%)     (%)                 
  ---------------- ---------- -------- ---------- ------- -------- ---------- ------- -------- ---------- -------
  CEA              Elevated   46       31                 53       24                 59       18         

                              (59.7)   (40.3)             (68.8)   (31.2)             (76.6)   (23.4)     

                   Normal     73       26         0.053   80       19         0.078   86       13         0.110

                              (73.7)   (26.3)             (80.8)   (19.2)             (86.9)   (13.1)     

  NSE              Elevated   26       27                 28       25                 36       17         

                              (49.1)   (50.9)             (52.8)   (47.2)             (67.9)   (32.1)     

                   Normal     91       27         0.000   103      15         0.000   106      12         0.001

                              (77.1)   (22.9)             (87.3)   (12.7)             (89.8)   (10.2)     

  Cyfra21-1        Elevated   42       20                 47       15                 52       10         

                              (67.7)   (32.3)             (75.8)   (24.2)             (83.9)   (16.1)     

                   Normal     75       36         1.000   84       27         1.000   91       20         0.836

                              (67.6)   (32.4)             (75.7)   (24.3)             (82.0)   (18.0)     

  CA199            Elevated   12       4                  12       4                  13       3          

                              (75.0)   (25.0)             (75.0)   (25.0)             (81.2)   (18.8)     

                   Normal     81       29         1.000   87       23         0.747   93       17         0.719

                              (73.6)   (26.4)             (79.1)   (20.9)             (84.5)   (15.5)     

  CA125            Elevated   33       12                 33       12                 36       9          

                              (73.3)   (26.7)             (73.3)   (26.7)             (80.0)   (20.0)     

                   Normal     55       18         0.830   60       13         0.258   64       9          0.298

                              (75.3)   (24.1)             (82.2)   (17.8)             (87.7)   (12.3)     

  SCC-Ag           Elevated   5        2                  6        1                  6        1          

                              (71.4)   (28.6)             (85.7)   (14.3)             (85.7)   (14.3)     

                   Normal     86       29         1.000   91       24         1.000   98       17         1.000

                              (74.8)   (25.2)             (79.1)   (20.9)             (85.2)   (14.8)     
  ---------------------------------------------------------------------------------------------------------------

###### 

Association between CTC count and serum NSE levels.

  CTC count   NSE level   Exp (B)   95% CI         P-value\*
  ----------- ----------- --------- -------------- -----------
  CTC ≥ 1     Normal      1.00      Reference      \-
              Elevated    2.953     1.302-6.698    0.010
  CTC ≥ 2     Normal      1.00      Reference      \-
              Elevated    4.446     1.785-11.070   0.001
  CTC ≥ 5     Normal      1.00      Reference      \-
              Elevated    2.914     1.072-7.922    0.036

\**P* value was adjusted by TNM stage (I, II, III and IV) and histology (SCLC and NSCLC).
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